Onishi Satoko, Inoue Yoshikazu, Inukai Maki, Okumoto Takayuki
Department of Plastic and Reconstructive Surgery, School of Medicine, Fujita Health University, Toyoake, Aichi, Japan.
Fujita Med J. 2022 May;8(2):42-45. doi: 10.20407/fmj.2020-029. Epub 2021 Aug 20.
Breast reconstruction using synthetic materials has increased rapidly in Japan since July 2013, when national health insurance began covering the procedure. Although synthetic material-based reconstruction of other body parts has not resulted in wounds with complications, this significant advantage is overshadowed by a risk of complications, including infection, following breast reconstruction. We therefore reviewed breast-reconstruction patients who experienced infection after implantation of synthetic materials and the countermeasures we used to address the problem.
From July 2013 through December 2019, our department performed primary breast reconstructions using tissue expanders (TEs) in 106 patients and secondary breast reconstructions in 39 patients. We retrospectively reviewed these 145 patients in terms of their age, body mass index, timing of the reconstruction, presence/absence of both chemotherapy and radiation therapy before and after surgery, presence/absence of postoperative wound complications, and presence/absence of atopic dermatitis. We then evaluated whether these factors put patients at risk for postoperative TE infection.
Among the 145 patients who underwent reconstruction with TE, 3 (2.0%) were diagnosed with a postoperative TE infection. Our review revealed that necrosis of the skin around the surgical wound (P=0.004) and atopic dermatitis (P=0.041) were risk factors for TE infection.
Infection following breast reconstruction with synthetic materials is a serious complication. Thus, patients requiring this surgery deserve optimal perioperative management. For those with known risk factors, a more appropriate surgical approach-e.g., using autologous tissue instead of a synthetic material-could be considered.
自2013年7月日本国民健康保险开始覆盖乳房重建手术以来,使用合成材料进行乳房重建的情况迅速增加。尽管基于合成材料的其他身体部位重建未导致伤口出现并发症,但乳房重建后包括感染在内的并发症风险掩盖了这一显著优势。因此,我们回顾了使用合成材料后发生感染的乳房重建患者以及我们用于解决该问题的对策。
2013年7月至2019年12月,我科对106例患者进行了使用组织扩张器(TE)的一期乳房重建,对39例患者进行了二期乳房重建。我们回顾性分析了这145例患者的年龄、体重指数、重建时间、手术前后是否接受化疗和放疗、术后伤口是否出现并发症以及是否患有特应性皮炎。然后评估这些因素是否使患者面临术后TE感染的风险。
在145例接受TE重建的患者中,3例(2.0%)被诊断为术后TE感染。我们的回顾显示,手术伤口周围皮肤坏死(P=0.004)和特应性皮炎(P=0.041)是TE感染的危险因素。
使用合成材料进行乳房重建后的感染是一种严重的并发症。因此,需要进行这种手术的患者应得到最佳的围手术期管理。对于那些已知有危险因素的患者,可以考虑采用更合适的手术方法,例如使用自体组织而非合成材料。